Eli Lilly and Company (NYSE:LLY) Shares Sold by TL Private Wealth

TL Private Wealth trimmed its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 7.5% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 621 shares of the company’s stock after selling 50 shares during the period. Eli Lilly and Company makes up approximately 0.2% of TL Private Wealth’s investment portfolio, making the stock its 23rd largest holding. TL Private Wealth’s holdings in Eli Lilly and Company were worth $464,000 as of its most recent filing with the SEC.

A number of other large investors also recently modified their holdings of LLY. Beck Bode LLC acquired a new position in shares of Eli Lilly and Company during the second quarter valued at $15,036,000. XTX Topco Ltd acquired a new position in shares of Eli Lilly and Company during the second quarter valued at $546,000. Westwood Holdings Group Inc. grew its holdings in Eli Lilly and Company by 1.9% during the second quarter. Westwood Holdings Group Inc. now owns 3,912 shares of the company’s stock worth $3,542,000 after acquiring an additional 73 shares during the period. Commonwealth Financial Services LLC grew its holdings in Eli Lilly and Company by 2.4% during the second quarter. Commonwealth Financial Services LLC now owns 822 shares of the company’s stock worth $755,000 after acquiring an additional 19 shares during the period. Finally, Certified Advisory Corp grew its holdings in Eli Lilly and Company by 3.6% during the second quarter. Certified Advisory Corp now owns 4,064 shares of the company’s stock worth $3,679,000 after acquiring an additional 142 shares during the period. 82.53% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 900 shares of Eli Lilly and Company stock in a transaction that occurred on Friday, November 8th. The stock was sold at an average price of $803.38, for a total value of $723,042.00. Following the transaction, the chief accounting officer now directly owns 5,480 shares of the company’s stock, valued at $4,402,522.40. The trade was a 14.11 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Company insiders own 0.13% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts recently issued reports on LLY shares. StockNews.com raised Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Wednesday, January 1st. Redburn Atlantic raised Eli Lilly and Company to a “hold” rating in a report on Monday, November 4th. Bank of America reaffirmed a “buy” rating and set a $997.00 target price on shares of Eli Lilly and Company in a report on Tuesday, December 10th. Wolfe Research began coverage on Eli Lilly and Company in a research report on Friday, November 15th. They issued an “outperform” rating and a $1,000.00 price target for the company. Finally, Deutsche Bank Aktiengesellschaft decreased their price target on Eli Lilly and Company from $1,025.00 to $1,015.00 and set a “buy” rating for the company in a research report on Monday, November 4th. Four analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $1,002.22.

Eli Lilly and Company Stock Down 4.1 %

Shares of LLY stock opened at $726.24 on Tuesday. The stock’s 50 day simple moving average is $781.14 and its 200 day simple moving average is $854.04. The company has a debt-to-equity ratio of 2.03, a quick ratio of 0.97 and a current ratio of 1.27. Eli Lilly and Company has a twelve month low of $612.70 and a twelve month high of $972.53. The company has a market capitalization of $689.43 billion, a price-to-earnings ratio of 78.51, a PEG ratio of 1.66 and a beta of 0.41.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Wednesday, October 30th. The company reported $1.18 earnings per share for the quarter, missing analysts’ consensus estimates of $1.52 by ($0.34). Eli Lilly and Company had a net margin of 20.48% and a return on equity of 71.08%. The company had revenue of $11.44 billion during the quarter, compared to the consensus estimate of $12.09 billion. During the same period in the previous year, the business posted $0.10 earnings per share. The firm’s revenue was up 20.4% on a year-over-year basis. As a group, research analysts predict that Eli Lilly and Company will post 13.14 EPS for the current year.

Eli Lilly and Company Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, March 10th. Shareholders of record on Friday, February 14th will be given a $1.50 dividend. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.30. This represents a $6.00 annualized dividend and a yield of 0.83%. The ex-dividend date of this dividend is Friday, February 14th. Eli Lilly and Company’s payout ratio is currently 56.22%.

Eli Lilly and Company declared that its Board of Directors has approved a stock buyback program on Monday, December 9th that allows the company to repurchase $15.00 billion in outstanding shares. This repurchase authorization allows the company to repurchase up to 2% of its shares through open market purchases. Shares repurchase programs are generally an indication that the company’s leadership believes its stock is undervalued.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.